Bettzy Stephen

In a Phase 2 study of people with rare cancers, researchers found that certain features of the tumor microenvironment may serve as predictive markers of response beyond what can currently be provided: spr.ly/6010BBhAEk @anaingmd #EndCancer

New #JITC article: "Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies" jitc.bmj.com/content/14/5/e… @ANaingMD @AmitaPatnaikMD

Colorectal cancer is rising in younger adults. Don’t miss this important webinar from Khin Naing Foundation USA featuring Dr. Scott Kopetz @skopetz @MDAndersonnews , a nationally recognized expert in colorectal cancer: “Understanding Colorectal Cancer: Awareness, Risk, and Early Action.” @OncoAlert @gillmorgan May 2, 2026 | 2:00 PM CT | 7:00 PM GMT | Zoom Free to attend; registration is required. Live Q&A included. Register: knfoundation-usa.com/scott-kopetz

We are excited to have Dr. Aung Naing speak at #IPOF2026 on April 11th! He will present on immune checkpoint inhibitors — exploring toxicity, resistance, & biomarker gaps in outcomes & strategies.Registration: innovationsjournals.m-pages.com/ipof-2026 #precisiononcology @OncologyNetwork @AnaingMD

On 2/7, Khin Naing Foundation proudly sponsored the Youth Entrepreneur Group of Great Houston for their participation in the JA Trade Fair at Memorial City Mall. We congratulate the young entrepreneurs on showcasing GhostChalk at this event organized by JA.

Khin Naing Foundation USA is pleased to host Michael Frei, PharmD, Clinical Pharmacy Specialist in the Melanoma & Sarcoma Departments at MD Anderson Cancer Center, for an inspiring session on “The Journey to Becoming a Pharmacist.” 📅 February 21 | 2:00 PM CDT 👉 Register here: knfoundation-usa.com/michael-frei

Limaye et al. explore "Exceptional Response to Immunotherapy-based Treatment in compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma" in a new #JIPO doi.org/10.36401/JIPO-… #immunotherapy #precisiononcology @DoubaZain @ANaingMD @OncologyNetwork @SewantiLimaye

Excited to announce the launch of the Youth Entrepreneurs Club of Greater Houston, a collaborative effort between @KhinNaingUSA, the Multicultural Center, and @JA_SET! The program helps high school students develop business plans, tackle real world challenges, and pitch ideas with guidance from experienced mentors. 🔗 Learn more: knfoundation-usa.com/youth-initiati… #YouthEntrepreneurs #HoustonYouth #KNFoundationUSA

Recharge Right: Sleep Hygiene for Students and Beyond Join Dr. Diwakar D. Balachandran, MD (for a free Zoom webinar! Sept 13, 2025 | 2 PM CST Learn how quality sleep boosts focus, health & academic success. 🔗 Register: knfoundation-usa.com/dr-balachandran #SleepMatters #StudentSuccess #SleepHealth #MentalWellness #BetterSleepBetterYou #SleepScience #FocusAndThrive #HealthyHabits #WebinarAlert #FreeEvent #SleepTips #BackToSchool #CollegeWellness #RechargeRight #KNFoundationUSA

New #JITC article: Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors bit.ly/4oD8LzK @AnishaPatelMD @cara_haymaker @ANaingMD @MDAndersonNews

Nardo et al: "Pembrolizumab in patients with advanced miscellaneous rare cancers: Results from a phase 2 basket trial" doi.org/10.36401/JIPO-… #precisiononcology #immunotherapy #raretumors #JIPO @mirella_nardo @CamilaBraganca @VivekSubbiah X @DavidHongMD @ANaingMD

@JIPOEditors @ANaingMD @InnoJournals @OncologyNetwork @jibranahmed1 @MekhailYN @MDerbalaMD @HafezMaria @CarlosTorradoMD @SewantiLimaye @weoncologists Congratulations!

#JIPO received its 1st official #impactfactor = 3.2! Immunology/Oncology Rank: Q2/Q3 We thank everyone who contributed to this achievement! @ANaingMD @InnoJournals @OncologyNetwork @jibranahmed1 @MekhailYN @mderbalamd @HafezMaria @CarlosTorradoMD @SewantiLimaye @weoncologists

Phase 2 trial of talabostat + pembrolizumab in advanced solid tumors: pubmed.ncbi.nlm.nih.gov/39853679/ safe but limited efficacy. DCR: 47%, 1 pt with MSS endometrial cancer had unconfirmed PR. mPFS: 2.7 m, mOS: 20.5 m. @jibranahmed1 @FilipJankuMD @ANaingMD @weoncologists @JournalCancer

@ANaingMD will be speaking at #JIPO's annual forum on April 5th in #Cincinnati. Virtual attendees can join online to listen and learn #IPOF2025 Reserve your spot at innovationsjournals.m-pages.com/WjNuqj/IPOF-20…

New #JITC article: TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial bit.ly/41kZWRa @ANaingMD @lillian_siu @MDAndersonNews @PMResearch_UHN

An important phase I study on endometrial cancer 🤓🤓 Temsirolimus+Metfomin 💊💊 ✅39% Clinical Benefit Rate ✅Relatively Low Rates of Gr3 AEs A combination for further evaluation pubmed.ncbi.nlm.nih.gov/39787747/ @ANaingMD @BettzyStephen @MDAndersonNews @FilipJankuMD @JournalCancer

@MDerbalaMD @ANaingMD Congratulations!!

First US phase 1 study of toripalimab in advanced malignancies shows manageable side effects & preliminary anti-tumor activity in patients with refractory cholangiocarcinoma (CCA). pubmed.ncbi.nlm.nih.gov/39816916/ #CancerResearch #Immunotherapy #Cholangiocarcinoma

Very happy to meet Dr. @PatrickHwuMD and Dr. @ANaingMD at #SITC2024 in Houston, TX, and get new insights on the latest trends in cancer immunotherapy and the gaps in knowledge that needs to be addressed. @sitcancer @BettzyStephen @MDAndersonNews

@MDerbalaMD @ANaingMD @MDAndersonNews @sitcancer #CancerResearch #AI #Immunotherapy

Huge congratulations @MDerbalaMD and members of Team @AnaingMD from @MDAndersonNews for oral presentation @sitcancer 2024! Artificial Intelligence-powered assessment of TME in pre-and on-treatment biopsies informs treatment outcomes to pembrolizumab in patients with rare tumors